Nerve Growth Factor (NGF) is a neurotrophin involved in the growth, maintenance, and survival of neurons. Its potential use in treating Bell’s Palsy—a condition characterized by sudden, unilateral facial nerve paralysis—has a basis in the scientific understanding of NGF’s neuroprotective and regenerative properties. Preclinical studies, mostly in animal models, have shown that NGF can promote the survival and regeneration of damaged facial nerve cells. For example, animal studies have demonstrated that exogenous NGF can enhance facial nerve recovery after injury by promoting axonal regeneration and reducing neuronal apoptosis.

Human evidence is limited but suggestive. A small number of clinical studies, most conducted in China, have explored the efficacy of NGF for Bell’s Palsy. These studies generally report improved outcomes in facial nerve recovery when NGF is administered, either alone or in combination with conventional therapies such as corticosteroids. However, the methodological quality of these studies is often poor—many lack rigorous randomization, double-blinding, or large sample sizes. There are also no large-scale, international trials validating NGF’s efficacy for Bell’s Palsy.

In summary, while there is a scientific rationale and some preliminary clinical evidence supporting the use of NGF for Bell’s Palsy, the overall level of evidence is low (rated 2/5). Widespread clinical use is not currently justified without further, high-quality research.